<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04131634</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1506</org_study_id>
    <nct_id>NCT04131634</nct_id>
  </id_info>
  <brief_title>Stereotactic Ablative Radiation for Oligo-Progression of Urothelial Cancer</brief_title>
  <acronym>SAbR</acronym>
  <official_title>A Phase II Trial of Stereotactic Ablative Radiation (SAbR) for Urothelial Cancer Patients With Progression While on Anti-PD-1/PD-L1 Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the benefit of SAbR for oligo-progressive metastatic urothelial cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oligo-progressive urothelial cancer with limited disease burden and progression on an
      anti-PD-1/L1 immune checkpoint inhibitor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2020</start_date>
  <completion_date type="Anticipated">November 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 16, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>Progression will be defined as the combination of progressive disease from SAbR start date, and death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Disease control rate (DCR) in patients for whom SAbR is added to ICI after progression on ICI. DCR will be assessed. To determine the time to initiation of next-line systemic therapy following the addition of SAbR to ICI after progression on ICI.
To determine the overall survival of patients since progression on ICI or at study registration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Urothelial Cancer</condition>
  <arm_group>
    <arm_group_label>SAbR 6 measurable lesions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-L1 assessment on biopsy of metastatic site (biopsy will be performed if no prior metastasis sample available)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Ablative Radiation</intervention_name>
    <description>A stereotactic relocalization system that relies upon stereoscopic radiographs, implanted fiducials, or near real-time CT based verification will be used.Investigators will have the discretion to choose from biologically equivalent dose levels using 1, 3 or 5 fractions. All active lesions need to be addressed by local therapy</description>
    <arm_group_label>SAbR 6 measurable lesions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be at least 18-years-old

          -  Patients must have pathology-proven metastatic urothelial carcinoma, with tissue
             sampling of at least the primary tumor

          -  Patients must be on immune checkpoint inhibitor therapy with radiographic scans to
             verify oligo-progression

          -  Women of child-bearing potential and men must agree to use adequate contraception
             prior to study entry, for the duration of study participation, and for 90 days
             following completion of therapy

        Exclusion Criteria:

          -  Inability to receive further immune checkpoint inhibitor therapy

          -  Anticipated survival of fewer than 12 weeks

          -  Steroid replacement therapy for adrenal insufficiency is permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurelie Garant</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liliana Robles</last_name>
    <phone>2146488038</phone>
    <email>lilianarobles@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aurelie Garant</last_name>
    <phone>214-645-8525</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aurelie Garant</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liliana Robles, MS</last_name>
      <phone>214-645-8525</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

